Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Phase 1 Trial of Combining Anti-CD47 Antibody (Magrolimab) with Azacitidine As Post-Transplant Maintenance Therapy in Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation for Treatment of High-Risk AML or MDS

NCT05823480 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT05823480
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05823480 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Phase 1 Trial of Combining Anti-CD47 Antibody (Magrolimab) with Azacitidine As Post-Transplant Maintenance Therapy in Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation for Treatment of High-Risk AML or MDS
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Withdrawn
Start date
October 9, 2024
Completion date
February 14, 2026
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, myelodysplastic syndrome